FLUDRUGSTRATEGY
Combating influenza using a novel drug strategy
| Coordinatore | VIRONOVA AB
Organization address
address: Gavlegatan 22 contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 1˙940˙609 € |
| EC contributo | 1˙498˙396 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-03-01 - 2010-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
VIRONOVA AB
Organization address
address: Gavlegatan 22 contact info |
SE (STOCKHOLM) | coordinator | 0.00 |
| 2 |
BEACTICA AB
Organization address
address: Box 567 contact info |
SE (UPPSALA) | participant | 0.00 |
| 3 |
INSTITUTE OF ORGANIC CHEMISTRY WITH CENTRE OF PHYTOCHEMISTRY - BULGARIAN ACADEMY OF SCIENCES
Organization address
address: Acad Georgi Bonchev street bld 9 contact info |
BG (SOFIA) | participant | 0.00 |
| 4 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 0.00 |
| 5 |
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Organization address
address: De Boelelaan 1105 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Objective: To find and produce novel target compounds against the influenza virus. Influenza A capsid protein is the target since it does not mutate at the same rate as the Hemagglutinin or Neuraminidase proteins. We aim to develop new therapeutic antiviral solutions to combat the disease. Beyond state of the art: The project combines knowledge based design and synthesis of compounds with unique patented image analysis and mathematical algorithm software to find and develop new types of potential antiviral molecules. The expertise and methodology allows for rapid discovery of lead molecules with the potential to provide new classes of drugs/vaccines which are less sensitive to viral mutation or reassortment. Work plan: Key molecules with optimal binding kinetics to the Influenza capsid protein will be designed and synthesized then analysed and tested in two separate experimental systems for their effect upon the virus structure and maturation process. The evaluation of novel lead drugs will be performed using a combination of new rapid image analysis, backed up by established viral analysis techniques. Finally a plan will be created for the continued verification and development of the lead molecules. Impact: We aim to produce a new class of antiviral drug candidates which specifically bind to influenza A capsid protein. These substances may have two potential effects; 1. Binding could inhibit important protein-protein interactions thereby inhibit virus formation. 2. Binding to the capsid protein could change the virus structure or stabilize the virus particle, resulting in non-infectious particles to which the host´s immune system could respond. The expected impact will be i) identification of targets against influenza to provide new therapeutic options ii) new opportunities to develop an anti-influenza vaccine which might help prevent an influenza pandemic, iii) to support the continued commercial development of the two SME partners.'